Mesoblast Refiles Biological License Application With the Us FDA for Cell Therapy; Shares Fall 6%
Mesoblast Refiles Biological License Application With the Us FDA for Cell Therapy; Shares Fall 6%
Mesoblast向美國FDA重新提交了細胞療法的生物許可申請；股價下跌了6%。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊